Plasma p-tau181 and amyloid markers in Alzheimer's disease: A comparison between Lumipulse and SIMOA

Virginia Quaresima¹, Andrea Pilotto², Chiara Trasciatti³, Chiara Tolassi¹, Marta Parigi⁴, Diego Bertoli⁵, Cristina Mordenti⁵, Alice Galli³, Andrea Rizzardi⁶, Salvatore Caratozzolo⁶, Alberto Benussi⁷, Nicholas J Ashton⁸, Kaj Blennow⁹, Henrik Zetterberg¹⁰, Silvia Giliani⁴, Duilio Brugnoni⁵, Alessandro Padovani¹¹

Affiliations

¹ Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; Department of continuity of care and frailty, Neurology Unit, ASST Spedali Civili Hospital, Brescia, Italy; Residency Program in Clinical Pathology and Clinical Biochemistry, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; Neurobiorepository and Laboratory of advanced biological markers, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy; A. Nocivelli Institute for Molecular Medicine Spedali Civili Hospital and Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
² Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; Department of continuity of care and frailty, Neurology Unit, ASST Spedali Civili Hospital, Brescia, Italy; Neurobiorepository and Laboratory of advanced biological markers, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy. Electronic address: pilottoandreae@gmail.com.
³ Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; Department of continuity of care and frailty, Neurology Unit, ASST Spedali Civili Hospital, Brescia, Italy; Neurobiorepository and Laboratory of advanced biological markers, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy.
⁴ A. Nocivelli Institute for Molecular Medicine Spedali Civili Hospital and Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
⁵ Central Clinical Laboratory, ASST Spedali Civili Hospital, Brescia, Italy.
⁶ Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; Department of continuity of care and frailty, Neurology Unit, ASST Spedali Civili Hospital, Brescia, Italy.
⁷ Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; Department of continuity of care and frailty, Neurology Unit, ASST Spedali Civili Hospital, Brescia, Italy; Neurology Clinic, Trieste University Hospital, Trieste, Italy.
⁸ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway; King's College London, Institute of Psychiatry, Psychology & Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK; NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation, London, UK; Banner Sun Health Research Institute, Sun City, AZ 85351, USA.
⁹ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation, London, UK; Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders, University of Science and Technology of China and First Affiliated Hospital of USTC, Hefei, PR China; Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France.
¹⁰ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK; UK Dementia Research Institute at UCL, London, UK; Department of Old Age Psychiatry, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, UK; Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China; Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.
¹¹ Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; Department of continuity of care and frailty, Neurology Unit, ASST Spedali Civili Hospital, Brescia, Italy; Neurobiorepository and Laboratory of advanced biological markers, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy; Brain Health Center, University of Brescia, Brescia, Italy.

PMID: 39208716
DOI: 10.1016/j.neurobiolaging.2024.08.007

Free article

Comparative Study

Plasma p-tau181 and amyloid markers in Alzheimer's disease: A comparison between Lumipulse and SIMOA

Virginia Quaresima et al. Neurobiol Aging. 2024 Nov.

Free article

. 2024 Nov:143:30-40.

doi: 10.1016/j.neurobiolaging.2024.08.007. Epub 2024 Aug 22.

Authors

Affiliations

¹ Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; Department of continuity of care and frailty, Neurology Unit, ASST Spedali Civili Hospital, Brescia, Italy; Residency Program in Clinical Pathology and Clinical Biochemistry, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; Neurobiorepository and Laboratory of advanced biological markers, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy; A. Nocivelli Institute for Molecular Medicine Spedali Civili Hospital and Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
² Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; Department of continuity of care and frailty, Neurology Unit, ASST Spedali Civili Hospital, Brescia, Italy; Neurobiorepository and Laboratory of advanced biological markers, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy. Electronic address: pilottoandreae@gmail.com.
³ Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; Department of continuity of care and frailty, Neurology Unit, ASST Spedali Civili Hospital, Brescia, Italy; Neurobiorepository and Laboratory of advanced biological markers, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy.
⁴ A. Nocivelli Institute for Molecular Medicine Spedali Civili Hospital and Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
⁵ Central Clinical Laboratory, ASST Spedali Civili Hospital, Brescia, Italy.
⁶ Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; Department of continuity of care and frailty, Neurology Unit, ASST Spedali Civili Hospital, Brescia, Italy.
⁷ Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; Department of continuity of care and frailty, Neurology Unit, ASST Spedali Civili Hospital, Brescia, Italy; Neurology Clinic, Trieste University Hospital, Trieste, Italy.
⁸ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway; King's College London, Institute of Psychiatry, Psychology & Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK; NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation, London, UK; Banner Sun Health Research Institute, Sun City, AZ 85351, USA.
⁹ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation, London, UK; Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders, University of Science and Technology of China and First Affiliated Hospital of USTC, Hefei, PR China; Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France.
¹⁰ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK; UK Dementia Research Institute at UCL, London, UK; Department of Old Age Psychiatry, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, UK; Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China; Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.
¹¹ Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; Department of continuity of care and frailty, Neurology Unit, ASST Spedali Civili Hospital, Brescia, Italy; Neurobiorepository and Laboratory of advanced biological markers, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy; Brain Health Center, University of Brescia, Brescia, Italy.

PMID: 39208716
DOI: 10.1016/j.neurobiolaging.2024.08.007

Abstract

Aim of the project was to evaluate the technical and clinical validity of plasma Lumipulse p-tau, Aβ42 and Aβ40 species and their correlation with CSF core Alzheimer's Disease (AD) markers; a method comparison with SIMOA was also performed. One-hundred-thirthy-three participants, namely 55 A+T+N+ AD, 28 Neurodegenerative disorders (NDD) and 50 controls were enrolled for the study. Lumipulse technical validity showed high stability for p-tau181, Aβ42, and Aβ40, with higher stability of p-tau to repeated freezing thaw cycles. p-tau181 levels detected by both techniques were higher in AD compared to both NDD/controls and exhibited a similar correlation with CSF p-tau levels, whereas Aβ42 levels were slightly lower in AD with both methods. In the comparison between SIMOA and Lumipulse plasma markers, both techniques exhibited similar diagnostic accuracy for AD for p-tau181 (0.87; 95 %CI 0.81-0.94, vs 0.85; 95 %CI 0.78-0.93), whereas the best performance was reached by p-tau181/ Aβ42 Lumipulse ratio (ROC AUC 0.915, 95 %CI 0.86-0.97). The study thus confirmed the construct validity of both Lumipulse and SIMOA techniques for the identification of CSF AD pattern in clinical settings.

Keywords: Alzheimer’s disease; CSF; Lumipulse; Plasma markers; SIMOA; Validation.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest APi received travel grants from Bial, Abbvie, Zambon pharma, Roche, Lundbeck pharma; he received grants from Bial, Biomarin, Abbvie, CHiesi, and Zambon pharmaceuticals. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). APa received grant support from Ministry of Health (MINSAL) and Ministry of Education, Research and University (MIUR), from CARIPLO Foundation; personal compensation as a consultant/scientific advisory board member for Biogen, Lundbeck, Roche, Nutricia, General Healthcare (GE).

References

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Plasma p-tau181 and amyloid markers in Alzheimer's disease: A comparison between Lumipulse and SIMOA

Affiliations

Plasma p-tau181 and amyloid markers in Alzheimer's disease: A comparison between Lumipulse and SIMOA

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources